Background: In the increasingly complex environment of MS there is a need for better cross-talk and communication between the different stakeholders who each address MS according to their own perspective.
Problem statement
Multiple sclerosis (MS) is classically regarded as an idiopathic inflammatory demyelinating and neurodegenerative disease of the central nervous system (CNS). It affects over 600,000 people living in Europe and involves around 1,000,000 caregivers and family members of patients with MS. 1 MS is to a large extent a women's disease (75% of patients entering current clinical trials are females) of which the incidence peaks at around 30 years of age, when people are at the top of their productive life, building their career, family life and social status. 2 About two-thirds of patients who present with an initial relapse (referred to as clinically isolated syndrome (CIS)) will develop clinically definite multiple sclerosis (CDMS). The majority of these patients (around 85%) first enter a relapsing-remitting phase (relapsing-remitting multiple sclerosis (RRMS)), but will eventually (after 8-20 years) have secondary progressive multiple sclerosis (SPMS), with fewer or no relapses but continuous progression of disability. 3 Approximately 15% of patients have primary progressive MS. 3 Although no two patients with MS are affected or progress in the same way, they can suffer from increasing mobility problems, fatigue, depression, cognitive decline, bladder and bowel problems, abnormal speech, double vision and sight impairments (leading to blindness in severe cases). In the majority of patients, MS will ultimately lead to an increasing use of walking aids and a wheelchair to remain mobile when they get older ( Figure 1 ). As such it is the leading cause of non-traumatic neurological disability in young adults in western countries. In addition to gradually increasing walking impairment, fatigue, depression and cognitive problems are considered very bothersome albeit less visible symptoms by MS patients. 4 All together, these symptoms are probably the reason why approximately half of patients with MS become unemployed within a decade 5 or even within a mean of 3 years after diagnosis 1 and have to live from a low disability pension for the rest of their life. This dramatically reduces the quality of life (QoL) and financial situation/independence of MS patients. Even patients with only mildmoderate disability (i.e. an Expanded Disability Status Scale (EDSS) of 3) have a similar or slightly lower health-related quality of life (HRQoL) utility of 0.56 to ~6.5 (as measured by the European Quality of life (EQ5D-5L) questionnaire on a scale from 1 (normal) to 0 (death)) 6,7 than patients with chronic ischaemic heart disease (0.64) 8 or non-insulin-dependent diabetes mellitus (0.67). 8 Moreover, this drops to 0.4 or lower if the MS patient becomes dependent on a wheelchair (i.e. at an EDSS > 6.5). 6, 7 It is obvious that the increasing disability and financial dependence of patients with MS also considerably impacts on the QoL and productivity of their caregivers and (other) family members ( Figure 1 ). As such not only MS patients but also their caregivers and family members pose a considerable (cost) burden on society.
Nevertheless, there seems to be insufficient understanding of the clinical, humanistic and cost burden associated with MS in society in general as well as with policy and decision makers. Moreover, evaluation of funding for MS by politicians and payers should be done relative to that for other chronic diseases such as cardiovascular disease, diabetes and/or Alzheimer.
There is currently no cure nor are there preventive measures for MS. However, early diagnosis and early treatment with disease-modifying drugs (DMDs; for RRMS or even CIS) can reduce relapse rate and/or slow down the progression of disability. This will improve the patients' ability to lead a full life and keep them longer mobile in order to continue social participation and work, keep their selfesteem and remain (financially) independent from their caregiver(s) and society support.
Unfortunately, access to quality care and treatment varies substantially among different member states in Europe (with very low access in eastern and southern Europe in 2013: Figure 2 ) 9 and healthcare systems (influenced by the economic situation) tend to push MS sufferers into an invalidity pension rather than keeping them active. The economic crisis, an ageing population and the availability of innovative but expensive healthcare technology and treatments all put pressure on healthcare budgets and their allocation. This carries the risk of a further reduction in access to care and treatment for patients with MS.
The patent expiry of several first-line DMDs in Europe (such as interferon β and glatiramer acetate) holds the promise of the availability of lower priced follow-on products, which may increase access to treatment. However, given the complexity of these DMDs, MS patients, their caregivers and healthcare professionals (HCPs) should be reassured by the health authorities that follow-on products have demonstrated similarity (based on appropriately established clinical methods) to the originator products with regard to long-term clinical efficacy and safety.
Rationale for the MS multi-stakeholder colloquia
It is clear that in this increasingly complex environment there is need for increased cross-talk and communication between the different stakeholders in MS in order to set, initiate and follow-up the key priorities The different stakeholders in MS all have their own perspectives and organisational platform: Surprisingly, there was until 2014 no initiative to increase the mutual understanding of each other's perspectives between the different stakeholders. Therefore, the first Pan-European MS Multistakeholder Colloquium was organised from 23-24 May 2014 in Brussels to enhance cross-talk and initiate collaboration between the major stakeholders ( Figure 3 ). The programme developed by Patrick Vermersch (the chair) and the other scientific committee members (Ralf Gold and Chris Holloway as co-chairs and Mondher Toumi and Frauke Zipp), with support from Ismar Healthcare, aimed at prioritising actions required to improve the quality of and access to care and treatment for MS in the midterm. 10 After introductory presentations on their perspectives by the different major stakeholders, the audience was asked to rank priorities from a list of potential Calls to Action. The outcome of this polling was used to stimulate further discussions among the speakers, a group of experts in the field and the audience, which formed the basis for formulating 10 integrated Calls to Action 11 (listed and described in the Conclusions of this supplement 12 In these proceedings, we summarise the content from the presentations, polling results and discussions for each of the stakeholders/perspectives as well as preliminary recommendations on how to tackle the Calls Figure 2 . Overall score and access-to-treatment score in European countries according to MS Barometer. 9 to Action, 12,14-18 which will also be addressed in the European Parliament.
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